Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADUS vs ARDT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARDT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–7 Matrix Metrics)

ARDT Overall Winner 6-Pillar Tally: ADUS 2 – 3 ARDT (1 Tie) Matrix Metrics: ADUS 7 – 3 ARDT

As of Nov 20, 2026, Ardent Health, Inc. (ARDT) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin).

  • Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. ARDT 40.2/100 SELL), ARDT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 10.4% operating margin) and revenue trajectory (+3.1% vs. +7.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADUS vs ARDT
ADUS NASDAQ
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74
ARDT NYSE Head-to-Head Winner
Ardent Health, Inc.
Services-General Medical & Surgical Hospitals, Nec
$15.08
+4.0% 1D
Market Cap $2.0B
TTM Revenue $6.45B
Forward P/E 10.9x
Beta / 30D Vol 0.01β · 115% Vol
Unified Composite Score
40.2 / 100 SELL
Tech 15.0 Fund 38.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.6% over 20 days), RSI 53
RSI-14: 52.8 · SMA20: $14.96 · SMA50: $12.65

6-Pillar Scorecard Institutional Category Breakdown (ADUS 2 – 3 ARDT)

Columns: Metric · ADUS · ARDT
1. Valuation Multiples ARDT
Forward P/E 16.1x 10.9x
Trailing P/E 20.1x 14.1x
PEG Ratio 1.05x N/M
EV / Revenue 1.5x 0.3x
2. Growth & Scale ADUS
Revenue Growth (YoY) +7.0% +3.1%
Earnings Growth (YoY) +24.2% -77.1%
TTM Revenue (USD) $1.50B $6.45B
Market Cap $2.3B $2.0B
3. Profitability & Quality ADUS
Gross Margin 32.3% 59.1%
Operating Margin 10.4% 5.1%
Net Profit Margin 7.4% 2.3%
Return on Equity (ROE) 10.0% 13.5%
4. Balance Sheet & Cash Flow ARDT
Cash Generation (TTM) $173M EBITDA $494M EBITDA
Cash Flow Margin 11.5% EBITDA Mgn 7.7% EBITDA Mgn
Net Cash / Leverage $64.64 Book/Sh · 10.0% ROE $9.91 Book/Sh · 13.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 21.9% (16th %ile) 53.1% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ARDT
OpEx & R&D Intensity 21.9% of Rev ($329M) 54.0% of Rev ($3.49B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADUS (7) vs ARDT (3)
Institutional Metric ADUS ARDT Criterion Row Edge
Market Capitalization
Scale
$2.3B $2.0B Larger Scale ADUS
Trailing P/E Ratio
Valuation
20.1x 14.1x Lower Multiple ARDT
Forward P/E Ratio
Valuation
16.1x 10.9x Lower Multiple ARDT
Revenue Growth (YoY)
Growth
+7.0% +3.1% Higher Growth ADUS
Operating Margin (TTM)
Profitability
10.4% 5.1% Higher Margin ADUS
Net Profit Margin
Profitability
7.4% 2.3% Higher Margin ADUS
Return on Equity (ROE)
Capital Efficiency
10.0% 13.5% Higher ROE ARDT
52-Week Range Position
Momentum
79% ($88–$132) 68% ($8–$19) Stronger Trend ADUS
Beta / 30D Volatility
Risk Regime
-0.07β · 21% Vol 0.01β · 115% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 40.2 / 100 (SELL) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$1.50B $6.45B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 59.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.05x PEG · 1.5x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$173M EBITDA ($64.64 Book/Sh · 10.0% ROE) $494M EBITDA ($9.91 Book/Sh · 13.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARDT +22.15 pp
ADUS: -0.14% · ARDT: +22.01%
3M Horizon ARDT +32.65 pp
ADUS: +1.39% · ARDT: +34.04%
6M Horizon ARDT +31.16 pp
ADUS: +32.22% · ARDT: +63.38%
1Y Horizon ARDT +62.35 pp
ADUS: +12.39% · ARDT: +74.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs ARDT. Trailing 12-month operating profitability (ADUS 10.4% vs ARDT 5.1%) and valuation multiples (ADUS 16.1x vs ARDT 10.9x Forward P/E) are benchmarked directly in Pillar 4 below.

ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x
ARDT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.45B
Gross Margin59.1%
Op. Margin5.1%
ROE / Fwd P/E13.5% · 10.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARDT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 53.1%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published
ARDT Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.0B market capitalization and 5.1% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($3.49B)
90D Engineering Disclosures 0 Published

Investor FAQ ADUS vs ARDT Key Questions & Quantitative Answers

As of Nov 20, 2026, Ardent Health, Inc. (ARDT) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin). Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. ARDT 40.2/100 SELL), ARDT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 10.4% operating margin) and revenue trajectory (+3.1% vs. +7.0% YoY).

ADUS leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with ARDT at +3.1% YoY revenue growth and -77.1% YoY earnings growth on $6.45B TTM revenue (59.1% gross margin, 5.1% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $6.45B for ARDT. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($3.49B) (0 disclosures) for ARDT.

ARDT screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas ARDT trades at 10.9x Forward P/E, 14.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (7.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus ARDT (13.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, ARDT carries 53.1% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 115% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.